Open-Systems-Pharmacology / Rifampicin-Tacrolimus-DDI

Rifampicin-Tacrolimus-DDI

Modeling of published clinical Rifampicin-Tacrolimus-DDI studies for model evaluation

Repository files

Within this repository, we distribute a PK-Sim snapshot containing simulations of all published clinical studies used to evaluate the predictive performance of the tacrolimus model regarding rifampicin-tacrolimus-DDIs, including the respective observed data digitized from literature reports. The applied rifampicin model has been published previously [1]. For further details and documentation please refer to [2].

Version information

PK-Sim Version 10.

Code of conduct

Everyone interacting in the Open Systems Pharmacology community (codebases, issue trackers, chat rooms, mailing lists etc...) is expected to follow the Open Systems Pharmacology code of conduct.

Contribution

We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the contribution guidelines. If you are contributing code, please be familiar with the coding standard.

License

The model is distributed under the GPLv2 Lincense.

Reference

[1] Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T. PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network for rifampicin, itraconazole, clarithromycin, midazolam, alfenatil and digoxin. CPT Pharmacometrics Syst Pharmacol 2018;7(10):647-659.

[2] Loer HLH, Feick D, Rüdesheim S, Selzer D, Schwab M, Teutonico D, Frechen S, van der Lee M, Moes DJAR, Swen JJ, Lehr T. Physiologically based pharmacokinetic modeling of tacrolimus for food-drug and CYP3A drug-drug-gene interaction predictions. CPT Pharmacometrics Syst Pharmacol 2023;00:1-15.